NCT03029208COMPLETEDanonymous

A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia in Chronic Kidney Disease (CKD)

Indication / condition

AI-normalized

Anaemia

Intervention

Source record

Daprodustat, Darbepoetin alfa, Iron therapy

Related intelligence directories

Indication directory: Anaemia Modality directory: small molecule Target directory: Anemia in Chronic Kidney Disease (CKD)

Source & freshness

Source record

NCT ID

NCT03029208

Original source

ClinicalTrials.gov

Source last updated

Oct 20, 2021

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03029208

Title

A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

PHASE3

Condition raw

Anaemia

Condition normalized

Anaemia

Modality raw

Anaemia

Modality normalized

small molecule

Target raw

Anemia in Chronic Kidney Disease (CKD)

Target normalized

Anemia in Chronic Kidney Disease (CKD)

Interventions

Daprodustat, Darbepoetin alfa, Iron therapy

Public preview

Source record

The ASCEND-ID trial evaluated daprodustat, a novel prolyl hydroxylase inhibitor, against darbepoetin alfa in treating anemia in CKD patients initiating dialysis. Conducted by GlaxoSmithKline, the study aimed to establish daprodustat's efficacy and safety over a 52-week period.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03029208

Status

COMPLETED

Phase

PHASE3

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedOct 20, 2021

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03029208

Indication

Anaemia

Modality

small molecule

Target

Anemia in Chronic Kidney Disease (CKD)

Intervention

Daprodustat, Darbepoetin alfa, Iron therapy

Source record